You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOlsalazine
Accession NumberDB01250
TypeSmall Molecule
GroupsApproved
DescriptionOlsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Mesalamine works as an anti-inflammatory agent in treating inflammatory diseases of the intestines.
Structure
Thumb
Synonyms
Dipentum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DipentumCapsule, gelatin coated250 mg/1OralMEDA Pharmaceuticals2015-05-15Not applicableUs
DipentumCapsule, gelatin coated250 mg/1OralCarilion Materials Management1990-07-31Not applicableUs
DipentumCapsule, gelatin coated250 mg/1OralAlaven Pharmaceutical LLC1990-07-31Not applicableUs
DipentumCapsule250 mgOralAtnahs Pharma Uk Limited1995-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Olsalazine sodium
6054-98-4
Thumb
  • InChI Key: QQWFSVYVHLECFP-XBPUGJBTSA-L
  • Monoisotopic Mass: 346.017775348
  • Average Mass: 346.2027
DBSALT000191
Categories
UNIIULS5I8J03O
CAS number15722-48-2
WeightAverage: 302.239
Monoisotopic: 302.053886062
Chemical FormulaC14H10N2O6
InChI KeyQQBDLJCYGRGAKP-FOCLMDBBSA-N
InChI
InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+
IUPAC Name
5-[(E)-2-(3-carboxy-4-hydroxyphenyl)diazen-1-yl]-2-hydroxybenzoic acid
SMILES
OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(O)C(=C1)C(O)=O
Pharmacology
IndicationFor the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.
Structured Indications
PharmacodynamicsOlsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine reduces the bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdominal pain. Like Balsalazide, Olsalazine is believed to deliver Mesalazine, or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is that active site of disease in ulcerative colitis.
Mechanism of actionOrally administered olsalazine is converted to mesalamine which is thought to be the therapeutically active agent in the treatment of ulcerative colitis. The mechanism of action of mesalamine (and sulfasalazine) is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid (AA) metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes (LTs) and hydroxyelcosatetraenoic acids (HETEs) is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin (PG) production in the colon.
TargetKindPharmacological actionActionsOrganismUniProt ID
Thiopurine S-methyltransferaseProteinyes
inhibitor
HumanP51580 details
Interferon gammaProteinyesNot AvailableHumanP01579 details
Related Articles
AbsorptionAfter oral administration, olsalazine, has limited systemic bioavailability. 98-99% of the dose is converted to mesalamine (5-ASA) in the colon, which is absorbed slowly resulting in very high local concentrations in the colon.
Volume of distributionNot Available
Protein bindingOlsalazine and olsalazine-S are more than 99% bound to plasma proteins. Mesalamine (5-ASA) is 74% bound to plasma proteins.
Metabolism

Most (98 to 99%) of an oral dose is rapidly converted into two molecules of 5-aminosalicylic acid (5-ASA) by colonic bacteria and the low prevailing redox potential found in this environment. The conversion of olsalazine to mesalamine in the colon is similar to that of sulfasalazine, which is converted into sulfapyridine and mesalamine. Approximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S)

SubstrateEnzymesProduct
Olsalazine
Not Available
Olsalazine-O-sulfateDetails
Route of eliminationApproximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S).The remaining 5-ASA is partially acetylated and is excreted in the feces.
Half lifeOlsalazine has an elimination half-life of 0.9 hours, however, olsalazine-S has a half-life of 7 days.
ClearanceNot Available
ToxicityMaximum single oral doses of 5g/kg in mice and rats and 2 g/kg in dogs were not lethal.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Olsalazine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Olsalazine is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Olsalazine is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Olsalazine is combined with 5-androstenedione.Experimental, Illicit
AbciximabOlsalazine may increase the anticoagulant activities of Abciximab.Approved
AcarboseOlsalazine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololOlsalazine may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacAceclofenac may increase the nephrotoxic activities of Olsalazine.Approved
AcenocoumarolOlsalazine may increase the anticoagulant activities of Acenocoumarol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneAcetovanillone may increase the nephrotoxic activities of Olsalazine.Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Olsalazine.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the nephrotoxic activities of Olsalazine.Approved, Vet Approved
AclarubicinOlsalazine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneAdapalene may increase the nephrotoxic activities of Olsalazine.Approved
AlbiglutideOlsalazine may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Alendronic acid.Approved
AliskirenOlsalazine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlogliptinOlsalazine may increase the hypoglycemic activities of Alogliptin.Approved
AlprenololOlsalazine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Olsalazine.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Alteplase.Approved
ALX-0081The risk or severity of adverse effects can be increased when Olsalazine is combined with ALX-0081.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Amcinonide.Approved
AmikacinOlsalazine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideOlsalazine may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Olsalazine.Approved
Ammonium chlorideThe serum concentration of Olsalazine can be increased when it is combined with Ammonium chloride.Approved, Vet Approved
AmrubicinOlsalazine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Olsalazine.Approved
AncrodOlsalazine may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Olsalazine is combined with Anecortave.Investigational
AnisodamineAnisodamine may increase the nephrotoxic activities of Olsalazine.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Anistreplase.Approved
annamycinOlsalazine may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may increase the nephrotoxic activities of Olsalazine.Approved
Antithrombin III humanOlsalazine may increase the anticoagulant activities of Antithrombin III human.Approved
AnvirzelThe serum concentration of Anvirzel can be decreased when it is combined with Olsalazine.Investigational
Aop200704Olsalazine may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanOlsalazine may increase the anticoagulant activities of Apixaban.Approved
ApramycinOlsalazine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastApremilast may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
ArbekacinOlsalazine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ardeparin.Approved, Withdrawn
ArgatrobanOlsalazine may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololOlsalazine may decrease the antihypertensive activities of Arotinolol.Approved
AstaxanthinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Astaxanthin.Investigational
AtenololOlsalazine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneAzapropazone may increase the nephrotoxic activities of Olsalazine.Withdrawn
AzathioprineThe metabolism of Azathioprine can be decreased when combined with Olsalazine.Approved
AzelastineAzelastine may increase the nephrotoxic activities of Olsalazine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Olsalazine.Approved
BalsalazideBalsalazide may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Batroxobin.Experimental
BecaplerminOlsalazine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololOlsalazine may decrease the antihypertensive activities of Befunolol.Experimental
BemiparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Bemiparin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Olsalazine.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olsalazine.Approved
BenoxaprofenBenoxaprofen may increase the nephrotoxic activities of Olsalazine.Withdrawn
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Olsalazine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Betamethasone.Approved, Vet Approved
BetaxololOlsalazine may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidBetulinic Acid may increase the nephrotoxic activities of Olsalazine.Investigational
BevantololOlsalazine may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Olsalazine.Approved, Investigational
BisoprololOlsalazine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinOlsalazine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololOlsalazine may decrease the antihypertensive activities of Bopindolol.Approved
BrinzolamideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Brinzolamide.Approved
BromfenacBromfenac may increase the nephrotoxic activities of Olsalazine.Approved
BromocriptineOlsalazine may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the nephrotoxic activities of Olsalazine.Investigational
BucindololOlsalazine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Budesonide.Approved
BufuralolOlsalazine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideOlsalazine may decrease the diuretic activities of Bumetanide.Approved
BupranololOlsalazine may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Olsalazine.Investigational
CanagliflozinOlsalazine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Olsalazine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Olsalazine.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Olsalazine.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Olsalazine.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Olsalazine.Approved
CarprofenCarprofen may increase the nephrotoxic activities of Olsalazine.Approved, Vet Approved, Withdrawn
CarteololOlsalazine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolOlsalazine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may increase the nephrotoxic activities of Olsalazine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Celecoxib.Approved, Investigational
CeliprololOlsalazine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Certoparin.Approved
ChloroquineChloroquine may increase the nephrotoxic activities of Olsalazine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olsalazine.Approved, Vet Approved
ChlorpropamideOlsalazine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Olsalazine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Olsalazine.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Olsalazine.Approved
CinoxacinOlsalazine may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinOlsalazine may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidOlsalazine may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may increase the nephrotoxic activities of Olsalazine.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Olsalazine.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Olsalazine.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Cortisone acetate.Approved
CurcuminCurcumin may increase the nephrotoxic activities of Olsalazine.Investigational
CyclosporineOlsalazine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may increase the nephrotoxic activities of Olsalazine.Investigational
Dabigatran etexilateOlsalazine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dalteparin.Approved
DanaparoidOlsalazine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinOlsalazine may increase the hypoglycemic activities of Dapagliflozin.Approved
DaunorubicinOlsalazine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Olsalazine is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Olsalazine.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Olsalazine is combined with dehydroepiandrosterone sulfate.Investigational
dersalazineOlsalazine may increase the anticoagulant activities of dersalazine.Investigational
DesirudinOlsalazine may increase the anticoagulant activities of Desirudin.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Olsalazine.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desmoteplase.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Olsalazine.Approved
DextranOlsalazine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Olsalazine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Olsalazine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Olsalazine may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Olsalazine.Approved, Vet Approved
DiclofenacDiclofenac may increase the nephrotoxic activities of Olsalazine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Diclofenamide.Approved
DicoumarolOlsalazine may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Diflorasone.Approved
DiflunisalDiflunisal may increase the nephrotoxic activities of Olsalazine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Olsalazine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Olsalazine.Approved
DihydrostreptomycinOlsalazine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Olsalazine.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Olsalazine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Olsalazine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Olsalazine.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Olsalazine.Approved
DisopyramideOlsalazine may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dorzolamide.Approved
DoxorubicinOlsalazine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneOlsalazine may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Olsalazine is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the nephrotoxic activities of Olsalazine.Approved
DulaglutideOlsalazine may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the nephrotoxic activities of Olsalazine.Investigational
E6201E6201 may increase the nephrotoxic activities of Olsalazine.Investigational
EbselenEbselen may increase the nephrotoxic activities of Olsalazine.Investigational
Edetic AcidOlsalazine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanOlsalazine may increase the anticoagulant activities of Edoxaban.Approved
EmpagliflozinOlsalazine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Olsalazine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Olsalazine.Approved
EnoxacinOlsalazine may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Enoxaparin.Approved
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Olsalazine.Approved, Investigational
EpirizoleEpirizole may increase the nephrotoxic activities of Olsalazine.Approved
EpirubicinOlsalazine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneOlsalazine may decrease the antihypertensive activities of Eplerenone.Approved
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Olsalazine.Investigational
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olsalazine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Olsalazine.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Olsalazine.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Olsalazine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Equilin.Approved
EsmololOlsalazine may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Estrone sulfate.Approved
Etacrynic acidOlsalazine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptEtanercept may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
EthoxzolamideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateOlsalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the nephrotoxic activities of Olsalazine.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the nephrotoxic activities of Olsalazine.Approved
ExenatideOlsalazine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the nephrotoxic activities of Olsalazine.Investigational
FenbufenFenbufen may increase the nephrotoxic activities of Olsalazine.Approved
FenoprofenFenoprofen may increase the nephrotoxic activities of Olsalazine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Olsalazine.Vet Approved
FibrinolysinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fibrinolysin.Approved
FleroxacinOlsalazine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Olsalazine.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Olsalazine is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fludrocortisone.Approved
FluindioneOlsalazine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineOlsalazine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Flunisolide.Approved, Investigational
FlunixinFlunixin may increase the nephrotoxic activities of Olsalazine.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Olsalazine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Flurandrenolide.Approved
FlurbiprofenFlurbiprofen may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Olsalazine.Approved, Nutraceutical, Vet Approved
FondaparinuxOlsalazine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumOlsalazine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Olsalazine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Olsalazine.Approved
FramycetinOlsalazine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideOlsalazine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateOlsalazine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinOlsalazine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinOlsalazine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Olsalazine.Approved, Withdrawn
GemifloxacinOlsalazine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinOlsalazine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinOlsalazine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AOlsalazine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Olsalazine.Approved, Nutraceutical
GliclazideOlsalazine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideOlsalazine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideOlsalazine may increase the hypoglycemic activities of Glipizide.Approved
GlyburideOlsalazine may increase the hypoglycemic activities of Glyburide.Approved
GrepafloxacinOlsalazine may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Olsalazine is combined with HE3286.Investigational
HeparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Heparin.Approved, Investigational
HigenamineHigenamine may increase the nephrotoxic activities of Olsalazine.Investigational
HirulogOlsalazine may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004HMPL-004 may increase the nephrotoxic activities of Olsalazine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olsalazine.Approved, Investigational
HydralazineOlsalazine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Olsalazine.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Olsalazine.Approved
Hygromycin BOlsalazine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ibandronate.Approved, Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Olsalazine.Approved, Investigational
IbuprofenIbuprofen may increase the nephrotoxic activities of Olsalazine.Approved
IbuproxamIbuproxam may increase the nephrotoxic activities of Olsalazine.Withdrawn
IcatibantIcatibant may increase the nephrotoxic activities of Olsalazine.Approved
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Olsalazine.Approved, Nutraceutical
IdarubicinOlsalazine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxOlsalazine may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Olsalazine.Approved, Withdrawn
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Olsalazine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Olsalazine.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Olsalazine.Approved
IndenololOlsalazine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Indobufen.Investigational
IndomethacinIndomethacin may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
IndoprofenIndoprofen may increase the nephrotoxic activities of Olsalazine.Withdrawn
INNO-206Olsalazine may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
Insulin AspartOlsalazine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirOlsalazine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineOlsalazine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineOlsalazine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanOlsalazine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproOlsalazine may increase the hypoglycemic activities of Insulin Lispro.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Olsalazine.Approved, Investigational
IsoxicamIsoxicam may increase the nephrotoxic activities of Olsalazine.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Olsalazine is combined with Istaroxime.Investigational
KanamycinOlsalazine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
Kct 0809The risk or severity of adverse effects can be increased when Olsalazine is combined with Kct 0809.Investigational
KebuzoneKebuzone may increase the nephrotoxic activities of Olsalazine.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Olsalazine.Investigational
KetoprofenKetoprofen may increase the nephrotoxic activities of Olsalazine.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Olsalazine.Approved
KetorolacKetorolac may increase the nephrotoxic activities of Olsalazine.Approved
LabetalolOlsalazine may decrease the antihypertensive activities of Labetalol.Approved
LanreotideOlsalazine may increase the hypoglycemic activities of Lanreotide.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Olsalazine.Approved, Investigational
LeflunomideLeflunomide may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
LepirudinOlsalazine may increase the anticoagulant activities of Lepirudin.Approved
LevobunololOlsalazine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinOlsalazine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Olsalazine.Approved
LiraglutideOlsalazine may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Olsalazine.Approved, Investigational
LisofyllineLisofylline may increase the nephrotoxic activities of Olsalazine.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Olsalazine.Approved
LomefloxacinOlsalazine may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamLornoxicam may increase the nephrotoxic activities of Olsalazine.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Olsalazine.Approved
LoxoprofenLoxoprofen may increase the nephrotoxic activities of Olsalazine.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Olsalazine.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Olsalazine.Vet Approved
Magnesium salicylateMagnesium salicylate may increase the nephrotoxic activities of Olsalazine.Approved
MasoprocolMasoprocol may increase the nephrotoxic activities of Olsalazine.Approved
ME-609The risk or severity of adverse effects can be increased when Olsalazine is combined with ME-609.Investigational
MecaserminOlsalazine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the nephrotoxic activities of Olsalazine.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Medrysone.Approved
Mefenamic acidMefenamic acid may increase the nephrotoxic activities of Olsalazine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Melengestrol.Vet Approved
MeloxicamMeloxicam may increase the nephrotoxic activities of Olsalazine.Approved, Vet Approved
MercaptopurineThe metabolism of Mercaptopurine can be decreased when combined with Olsalazine.Approved
MesalazineMesalazine may increase the nephrotoxic activities of Olsalazine.Approved
MetamizoleMetamizole may increase the nephrotoxic activities of Olsalazine.Withdrawn
MetforminOlsalazine may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Olsalazine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olsalazine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Methylprednisolone.Approved, Vet Approved
MetipranololOlsalazine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Olsalazine.Approved
MetoprololOlsalazine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideOlsalazine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneOlsalazine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolOlsalazine may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Olsalazine.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Olsalazine.Approved
MizoribineMizoribine may increase the nephrotoxic activities of Olsalazine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Olsalazine.Approved
MometasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Olsalazine.Approved
MoxifloxacinOlsalazine may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the nephrotoxic activities of Olsalazine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nabumetone.Approved
NadololOlsalazine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nadroparin.Approved
NafamostatNafamostat may increase the nephrotoxic activities of Olsalazine.Investigational
NaftifineNaftifine may increase the nephrotoxic activities of Olsalazine.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Olsalazine.Investigational
Nalidixic AcidOlsalazine may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenNaproxen may increase the nephrotoxic activities of Olsalazine.Approved, Vet Approved
NateglinideOlsalazine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Olsalazine is combined with NCX 1022.Investigational
NCX 4016NCX 4016 may increase the nephrotoxic activities of Olsalazine.Investigational
NeamineOlsalazine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinOlsalazine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinOlsalazine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacNepafenac may increase the nephrotoxic activities of Olsalazine.Approved
NetilmicinOlsalazine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may increase the nephrotoxic activities of Olsalazine.Approved
NimesulideNimesulide may increase the nephrotoxic activities of Olsalazine.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Olsalazine.Investigational
NorfloxacinOlsalazine may increase the neuroexcitatory activities of Norfloxacin.Approved
OctreotideOlsalazine may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OfloxacinOlsalazine may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Olsalazine.Approved, Investigational
OlopatadineOlopatadine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Olsalazine.Investigational
OrgoteinOrgotein may increase the nephrotoxic activities of Olsalazine.Vet Approved
OtamixabanOlsalazine may increase the anticoagulant activities of Otamixaban.Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Olsalazine.Approved
OxaprozinOxaprozin may increase the nephrotoxic activities of Olsalazine.Approved
OxprenololOlsalazine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneOxyphenbutazone may increase the nephrotoxic activities of Olsalazine.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Parecoxib.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Parnaparin.Approved
ParomomycinOlsalazine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PasireotideOlsalazine may increase the hypoglycemic activities of Pasireotide.Approved
PazufloxacinOlsalazine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinOlsalazine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololOlsalazine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineOlsalazine may increase the hypoglycemic activities of Pentamidine.Approved
Pentosan PolysulfateOlsalazine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Olsalazine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Olsalazine.Approved
PhenindioneOlsalazine may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonOlsalazine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the nephrotoxic activities of Olsalazine.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
PindololOlsalazine may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneOlsalazine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirarubicinOlsalazine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideOlsalazine may decrease the diuretic activities of Piretanide.Experimental
PirfenidonePirfenidone may increase the nephrotoxic activities of Olsalazine.Investigational
PiroxicamPiroxicam may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
PlasminThe risk or severity of adverse effects can be increased when Olsalazine is combined with Plasmin.Investigational
PlicamycinOlsalazine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Olsalazine.Approved
PractololOlsalazine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Olsalazine.Approved
PramlintideOlsalazine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prasterone.Approved, Nutraceutical
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Olsalazine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Olsalazine can be increased when it is combined with Probenecid.Approved
PropacetamolPropacetamol may increase the nephrotoxic activities of Olsalazine.Approved
PropranololOlsalazine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Olsalazine.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Olsalazine.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Olsalazine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Olsalazine.Vet Approved
Protein COlsalazine may increase the anticoagulant activities of Protein C.Approved
Protein S humanOlsalazine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeOlsalazine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinOlsalazine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299PTC299 may increase the nephrotoxic activities of Olsalazine.Investigational
PuromycinOlsalazine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Olsalazine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Olsalazine.Approved
QuinineOlsalazine may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Olsalazine.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Olsalazine.Approved
RepaglinideOlsalazine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Olsalazine.Approved
ResveratrolResveratrol may increase the nephrotoxic activities of Olsalazine.Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Reteplase.Approved
ReviparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Reviparin.Approved
RibostamycinOlsalazine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Olsalazine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Risedronate.Approved, Investigational
RivaroxabanOlsalazine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Rosiglitazone.Approved, Investigational
RosoxacinOlsalazine may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Olsalazine.Approved
SalicylamideSalicylamide may increase the nephrotoxic activities of Olsalazine.Approved
Salicylic acidSalicylic acid may increase the nephrotoxic activities of Olsalazine.Approved, Vet Approved
SalsalateSalsalate may increase the nephrotoxic activities of Olsalazine.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Olsalazine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Olsalazine.Investigational
SaxagliptinOlsalazine may increase the hypoglycemic activities of Saxagliptin.Approved
SCH-530348The risk or severity of adverse effects can be increased when SCH-530348 is combined with Olsalazine.Investigational
SelexipagThe risk or severity of adverse effects can be increased when Olsalazine is combined with Selexipag.Approved
SeratrodastSeratrodast may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Olsalazine.Approved, Vet Approved
SisomicinOlsalazine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitagliptinOlsalazine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SotalolOlsalazine may decrease the antihypertensive activities of Sotalol.Approved
SP1049COlsalazine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinOlsalazine may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinOlsalazine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Olsalazine.Approved
SpironolactoneOlsalazine may decrease the antihypertensive activities of Spironolactone.Approved
SRT501SRT501 may increase the nephrotoxic activities of Olsalazine.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Streptokinase.Approved
StreptomycinOlsalazine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinOlsalazine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineOlsalazine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleOlsalazine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the nephrotoxic activities of Olsalazine.Approved
SulfisoxazoleOlsalazine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the nephrotoxic activities of Olsalazine.Approved
SulodexideOlsalazine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Olsalazine.Investigational
SunitinibOlsalazine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the nephrotoxic activities of Olsalazine.Approved, Withdrawn
TacrolimusOlsalazine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Olsalazine.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Olsalazine.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Olsalazine.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Olsalazine.Approved, Investigational
TemafloxacinOlsalazine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Olsalazine.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tenecteplase.Approved
TenofovirThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may increase the nephrotoxic activities of Olsalazine.Approved
TepoxalinTepoxalin may increase the nephrotoxic activities of Olsalazine.Vet Approved
TeriflunomideTeriflunomide may increase the nephrotoxic activities of Olsalazine.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Olsalazine.Investigational
Tiaprofenic acidTiaprofenic acid may increase the nephrotoxic activities of Olsalazine.Approved
TicagrelorThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Olsalazine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tiludronate.Approved, Vet Approved
TimololOlsalazine may decrease the antihypertensive activities of Timolol.Approved
TinoridineTinoridine may increase the nephrotoxic activities of Olsalazine.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tinzaparin.Approved
TioguanineThe metabolism of Tioguanine can be decreased when combined with Olsalazine.Approved
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Olsalazine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tixocortol.Approved
TobramycinOlsalazine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazamideOlsalazine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideOlsalazine may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the nephrotoxic activities of Olsalazine.Approved
TolmetinTolmetin may increase the nephrotoxic activities of Olsalazine.Approved
TorasemideOlsalazine may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Olsalazine.Approved
TranilastTranilast may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Olsalazine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Olsalazine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Olsalazine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneOlsalazine may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Olsalazine.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Olsalazine.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the nephrotoxic activities of Olsalazine.Approved
TrovafloxacinOlsalazine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Olsalazine.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Olsalazine.Approved, Investigational
ValrubicinOlsalazine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Olsalazine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Olsalazine.Approved
VerapamilVerapamil may increase the anticoagulant activities of Olsalazine.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Olsalazine.Approved
WarfarinOlsalazine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranOlsalazine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Olsalazine may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenZaltoprofen may increase the nephrotoxic activities of Olsalazine.Approved
ZileutonZileuton may increase the nephrotoxic activities of Olsalazine.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Zoledronic acid.Approved
ZomepiracZomepirac may increase the nephrotoxic activities of Olsalazine.Withdrawn
ZorubicinOlsalazine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesA07EC03
AHFS Codes
  • 56:36.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8502
Blood Brain Barrier+0.6279
Caco-2 permeable-0.6449
P-glycoprotein substrateNon-substrate0.7433
P-glycoprotein inhibitor INon-inhibitor0.8628
P-glycoprotein inhibitor IINon-inhibitor0.9525
Renal organic cation transporterNon-inhibitor0.8844
CYP450 2C9 substrateNon-substrate0.7774
CYP450 2D6 substrateNon-substrate0.8748
CYP450 3A4 substrateNon-substrate0.6636
CYP450 1A2 substrateNon-inhibitor0.8006
CYP450 2C9 inhibitorNon-inhibitor0.7804
CYP450 2D6 inhibitorNon-inhibitor0.9047
CYP450 2C19 inhibitorNon-inhibitor0.8638
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8912
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.5546
BiodegradationNot ready biodegradable0.8701
Rat acute toxicity1.4882 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9506
hERG inhibition (predictor II)Non-inhibitor0.9453
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral250 mg
Capsule, gelatin coatedOral250 mg/1
Prices
Unit descriptionCostUnit
Dipentum 250 mg capsule1.8USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting pointSodium salt decomposes at 240 °CNot Available
logP2.3Not Available
Caco2 permeability-6.96ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0781 mg/mLALOGPS
logP2.77ALOGPS
logP4.39ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)2.93ChemAxon
pKa (Strongest Basic)-0.019ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area139.78 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.85 m3·mol-1ChemAxon
Polarizability28.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as azobenzenes. These are organonitrogen aromatic compounds that contain a central azo group, where each nitrogen atom is conjugated to a bezene ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzobenzenes
Sub ClassNot Available
Direct ParentAzobenzenes
Alternative Parents
Substituents
  • Azobenzene
  • Salicylic acid
  • Salicylic acid or derivatives
  • Hydroxybenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzoyl
  • Phenol
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous acid
  • Azo compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thiopurine s-methyltransferase activity
Specific Function:
Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine.
Gene Name:
TPMT
Uniprot ID:
P51580
Molecular Weight:
28180.09 Da
References
  1. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, Nierenberg DW: Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther. 1997 Oct;62(4):464-75. [PubMed:9357398 ]
  2. Lennard L: TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002 Aug;51(2):143-6. [PubMed:12117866 ]
  3. Lennard L: Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions. Ther Drug Monit. 1998 Oct;20(5):527-31. [PubMed:9780130 ]
  4. Shipkova M, Niedmann PD, Armstrong VW, Oellerich M, Wieland E: Determination of thiopurine methyltransferase activity in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by sulfasalazine. Clin Chem. 2004 Feb;50(2):438-41. [PubMed:14752016 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Interferon-gamma receptor binding
Specific Function:
Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.
Gene Name:
IFNG
Uniprot ID:
P01579
Molecular Weight:
19348.165 Da
References
  1. Egan LJ, Sandborn WJ: Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology. 1998 Nov;115(5):1295-6. [PubMed:9797390 ]
  2. Ito R, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J, Imanishi J, Kita M, Ueda Y, Iwakura Y, Kataoka K, Okanoue T, Mazda O: Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 2006 Nov;146(2):330-8. [PubMed:17034586 ]
Comments
comments powered by Disqus
Drug created on March 30, 2007 06:25 / Updated on August 17, 2016 12:23